Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.8750.

Several analysts have issued reports on the company. Maxim Group cut their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Wall Street Zen cut Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Finally, Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a report on Friday. They issued a “buy” rating and a $7.50 price objective for the company.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $4.25 on Monday. The firm has a fifty day moving average of $4.54 and a two-hundred day moving average of $3.89. The firm has a market cap of $69.96 million, a P/E ratio of -9.04 and a beta of 1.22. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The company had revenue of $4.94 million during the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. On average, sell-side analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors have recently modified their holdings of the business. Pacific Ridge Capital Partners LLC raised its stake in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares during the period. Divisadero Street Capital Management LP grew its holdings in shares of Sensus Healthcare by 39.5% during the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after purchasing an additional 128,224 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sensus Healthcare by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after purchasing an additional 5,316 shares during the last quarter. Sachetta LLC raised its position in shares of Sensus Healthcare by 6.8% during the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after purchasing an additional 9,500 shares during the period. Finally, Greenline Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth approximately $513,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.